- Home
- EGY vs AQST Comparison
EGY vs AQST Comparison
Compare EGY & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- AQST
- Stock Information
- Founded
- EGY 1985
- AQST 2004
- Country
- EGY United States
- AQST United States
- Employees
- EGY N/A
- AQST N/A
- Industry
- EGY Oil & Gas Production
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- AQST Health Care
- Exchange
- EGY Nasdaq
- AQST Nasdaq
- Market Cap
- EGY 399.3M
- AQST 390.4M
- IPO Year
- EGY N/A
- AQST 2018
- Fundamental
- Price
- EGY $4.31
- AQST $4.94
- Analyst Decision
- EGY
- AQST Strong Buy
- Analyst Count
- EGY 0
- AQST 7
- Target Price
- EGY N/A
- AQST $10.29
- AVG Volume (30 Days)
- EGY 727.2K
- AQST 2.3M
- Earning Date
- EGY 11-10-2025
- AQST 11-03-2025
- Dividend Yield
- EGY 5.81%
- AQST N/A
- EPS Growth
- EGY N/A
- AQST N/A
- EPS
- EGY 0.37
- AQST N/A
- Revenue
- EGY $469,277,000.00
- AQST $44,132,000.00
- Revenue This Year
- EGY N/A
- AQST N/A
- Revenue Next Year
- EGY $23.20
- AQST $51.50
- P/E Ratio
- EGY $11.68
- AQST N/A
- Revenue Growth
- EGY N/A
- AQST N/A
- 52 Week Low
- EGY $3.00
- AQST $2.12
- 52 Week High
- EGY $6.45
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- EGY 67.70
- AQST 61.01
- Support Level
- EGY $3.95
- AQST $4.78
- Resistance Level
- EGY $4.35
- AQST $5.27
- Average True Range (ATR)
- EGY 0.14
- AQST 0.30
- MACD
- EGY 0.04
- AQST 0.02
- Stochastic Oscillator
- EGY 92.98
- AQST 64.71
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea, and Cote d'Ivoire. The company generates maximum revenue from the Gabon segment.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.